Cell & Gene Therapy (CGT)

The CGT revolution in India is accelerating, but the gap between "marketing claims" and "clinical readiness" is vast. A single misstep in vector yield, capsid purity, or tech transfer can derail your program.

Cell & Gene Therapy (CGT)

Cell & Gene Therapies demand flawless execution, yet India's nascent ecosystem amplifies risks: overstated capabilities, titer variability, and regulatory grey zones.

Aventiq Bio specializes in advisory-only services - stress-testing selected partners for plasmid production, viral vectors, analytics, and tech transfer - enabling you to leverage India's talent depth and 50–70% cost advantages with eyes wide open.

India's Evolving CGT Ecosystem – Talent-Driven Potential

India's CGT landscape is clinical-scale focused, with 10+ facilities excelling in plasmid DNA, AAV/lentiviral vectors, and advanced analytics (ddPCR, flow cytometry). The real strength lies in a massive pool of molecular biologists and virologists - delivering high-quality data at fraction of Western costs. Commercial-scale is emerging (2026–2028), making it ideal for early-phase and "China+1" strategies. Aventiq Bio scouts and evaluates these partners transparently, prioritizing analytical talent and process robustness.

Yield Gap & Capsid Variability

Low vector titers and poor empty-vs-full capsid ratios from unoptimized processes
Raw Material Trap

Unreliable local sourcing of high-grade pDNA, media, or transfection reagents
Facility Maintenance Culture

Cleanrooms claiming GMP but lacking sustained ISO class compliance or operator discipline.
Regulatory Grey Zones

Aligning evolving Indian RCGM/CDSCO rules with FDA/EMA ATMP standards.
Tech Transfer "Blind Spots"

Potency loss or impurity spikes during process handover

Stress-Tested Guidance Across CGT Development Stages

We organize advisory around technical maturity stages - evaluating partners and planning for global readiness.

Partner Scouting Maturity Benchmarking

Scouting for plasmid/AAV/lentiviral facilities
50-point CGT Readiness Matrix scoring (infrastructure, talent, track record)
The Aventiq Edge: Identifying the 1% truly capable today

Technical Evaluation Purity & Titer Audits

Verifying empty-vs-full capsid ratios and HCP levels
Analytical talent scouting (ddPCR, NGS, potency assays)
The Aventiq Edge: Pre-identifying titer-drop risks before commitment

Regulatory Bridge Global ATMP Alignment

Ensuring data acceptance by FDA/EMA (comparability, release testing)
Capacity reservation advisory in limited-suite market
The Aventiq Edge: Bridging Indian GMP with international ATMP guidelines

Tech Transfer Risk-Mapping Pre-Identifying Potency-Loss Risks

Advisory for process handover (upstream/downstream)
Raw material and supply chain evaluation
The Aventiq Edge: Pre-identifying tilter-drop risks before commitment and bridging Indian GMP with International ATMP guidelines

Why choose Aventiq Bio for CGT

Independent auditor with no facility ties in a nascent market. Deep focus on analytical sensitivity, yield consistency, and empty/full ratio control. Proprietary maturity matrix that surfaces the truly capable partners today. On-ground insight into talent density and maintenance culture. Track record guiding early CGT programs so vector quality, data integrity, and global regulatory acceptance are protected from day one.

Cell & Gene Therapy (CGT)